Company: HROW
Filing Date: 2025-11-10
Form Type: 10-Q
Source: 0001493152-25-021562
Chunk: 112

Company: HARROW, INC.
Filing Date: 2025-11-10
Form: 10-Q
Item: Item 3
Chunk 112
---
udited condensed consolidated financial statements included in this Quarterly Report for information on various legal
proceedings, which is incorporated into this Item by reference.

Item
1A. Risk Factors

In
addition to the other information contained in this Quarterly Report you should consider the risk factors and the other information in
our Annual Report on Form 10-K for the year ended December 31, 2024, including our audited financial statements and the related notes
and “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” If any such risks actually
occur, our business, financial condition, results of operations and future growth prospects would likely be materially and adversely
affected. In these circumstances, the market price of our common stock would likely decline and you may lose all or part of your investment.
Additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business operations.

Below
we provide in supplemental form the material changes to our risk factors as previously disclosed in Part I, Item 1A, of our Annual Report
on Form 10-K for the year ended December 31, 2024. Our risk factors disclosed in the Annual Report on Form 10-K provide additional disclosure
for these supplemental risks and are incorporated herein by reference.

Disruptions
at the FDA, CMS, the SEC, and other government agencies resulting from the U.S. government shutdown and reported staffing reductions
could adversely affect our operations, regulatory interactions, and access to capital.

A
prolonged or repeated shutdown of the U.S. federal government, or other significant disruptions to the operations of federal agencies,
could adversely affect our business, financial condition, and results of operations. The U.S. government shutdown that began on October
1, 2025 has caused many federal agencies to scale back operations and furlough portions of their workforce. Certain agencies that are
important to our business, including the U.S. Department of Health and Human Services (“HHS”) and its operating divisions
such as the Centers for Medicare & Medicaid Services (“CMS”) and the FDA, and the SEC, may experience resource
constraints or temporary delays in certain activities as a result of the shutdown or related funding limitations. Any such disruptions
could delay the FDA’s review and processing of submissions, the CMS’s issuance of reimbursement guidance, or the SEC’s
review of our filings, which could in turn affect our ability to develop, market, and sell our products or raise capital in a timely